Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1821 results
June 2021
-
Media ReleaseNovartis and Hewlett Packard Enterprise join forces to advance Novartis global health effortsNovartis is collaborating with Hewlett Packard Enterprise to accelerate the use of data and digital technologies within its efforts to reimagine global health and improve access to healthcare and…
-
Media ReleaseKesimpta® (ofatumumab) data show long-term preservation of IgG/IgM levels and no increased risk of serious infections in people living with multiple sclerosisNew ALITHIOS data show mean immunoglobulin G (IgG) levels in people treated with Kesimpta remained unchanged over 3.5 years and mean immunoglobulin M (IgM) levels remained within the reference range1…
-
The search for new options for patients with lung cancer
We’re working to bring the hope of advanced medicine to more patients.
-
Discover how inflammation could fan the flames of cancer
Targeting inflammation to fight cancer is a new approach with a long history.
-
Media ReleaseNew Zolgensma data demonstrate age-appropriate development when used presymptomatically and rapid, clinically meaningful efficacy in symptomatic children, even those with severe SMA at baselineAll children (100%) treated presymptomatically in the SPR1NT two-copy cohort survived without respiratory or nutritional support, and sat independently for ≥30 seconds, most (11/14) within the WHO…
-
Pulse UpdateNovartis receives FDA Breakthrough Therapy designation for investigational 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC)
-
In The NewsNovartis CEO outlines how to improve pandemic preparedness, warns another one is bound to happenNovartis CEO Vas Narasimhan discusses how to improve pandemic preparedness at the CNBC Evolve Global Summit.
-
Media ReleaseNovartis investigational oral therapy iptacopan (LNP023) shows benefit as monotherapy in treatment-naïve patients with rare and life-threatening blood disorder paroxysmal nocturnal hemoglobinuriaFirst-in-class, oral, targeted factor B inhibitor iptacopan substantially reduced both intra- and extravascular hemolysis when given as monotherapy in a Phase II study of anti-C5 naïve paroxysmal…
-
Pulse UpdateNovartis Entresto® indicated for treatment of hypertension in China
-
Media ReleaseNovartis announces new interim analysis Phase II data for iptacopan in rare kidney disease C3 glomerulopathy (C3G)Data shows investigational iptacopan improved estimated glomerular filtration rate (eGFR) slope and stabilized kidney function in patients with C3G1; Phase III clinical trial to start in 2021…
-
Media ReleaseNovartis announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA nephropathy (IgAN)Phase II primary endpoint results for investigational iptacopan in IgAN demonstrated effective and clinically meaningful reduction of proteinuria1 – a key risk predictor in kidney disease…
-
Media ReleaseNovartis announces Tabrecta® first published overall survival and updated overall response data in patients with METex14 metastatic NSCLCTabrecta® (capmatinib) showed a median overall survival (OS) of 20.8 months in treatment-naïve patients and 13.6 months in previously-treated patients in first published mature data1,2 Tabrecta…
Pagination
- ‹ Previous page
- 1
- …
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- …
- 152
- › Next page